Hormone Replacement Therapy (HRT): Benefits, Risks, and Options

Hormone replacement therapy encompasses a range of medical interventions that supplement or replace hormones — primarily estrogen, progesterone, and testosterone — whose levels decline during perimenopause, menopause, or as a result of surgical removal of the ovaries. This page covers the clinical definitions, delivery mechanisms, established risk-benefit evidence, classification boundaries between formulation types, and the major points of ongoing scientific debate. The evidence base for HRT has shifted substantially since the Women's Health Initiative (WHI) trials published findings in 2002, making an accurate understanding of current research essential for informed clinical conversations.

Table of Contents

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix

Definition and Scope

Hormone replacement therapy refers to exogenous administration of one or more hormones to compensate for endogenous deficiency. The most common clinical indication in women is the menopause transition, during which ovarian estrogen production falls to a fraction of premenopausal levels — by approximately 90% in postmenopausal women compared with reproductive-age baseline (NIH National Institute on Aging).

HRT scope extends across three distinct populations:

• Perimenopausal and postmenopausal women managing vasomotor symptoms, genitourinary changes, or bone loss
• Surgically menopausal women (post-oophorectomy), who experience abrupt hormonal decline rather than gradual transition
• Women with primary ovarian insufficiency (POI), affecting approximately 1% of women under age 40 (ACOG Practice Bulletin No. 234)

Regulatory oversight in the United States falls under the Food and Drug Administration (FDA), which approves specific hormone formulations, dosages, and labeled indications. The regulatory context for women's health shapes which formulations are approved, how labeling must characterize risks, and what off-label prescribing is permitted within clinical discretion.

Core Mechanics or Structure

HRT acts by binding to intracellular or membrane-bound hormone receptors distributed throughout multiple organ systems — including the hypothalamus, bone, cardiovascular endothelium, urogenital epithelium, and skin. The primary hormone components are:

Estrogen: The principal active agent for vasomotor and genitourinary symptom relief. Estrogen receptors alpha (ERα) and beta (ERβ) mediate distinct tissue responses. ERα predominates in uterine and breast tissue; ERβ predominates in bone and the cardiovascular system (NIH National Library of Medicine, NCBI Bookshelf, StatPearls — Hormone Replacement Therapy).

Progestogen: Added to estrogen regimens in women with an intact uterus to prevent endometrial hyperplasia, which untreated carries a risk of progression to endometrial carcinoma. Two sub-types exist: synthetic progestins (medroxyprogesterone acetate, norethindrone) and micronized progesterone (bioidentical, chemically identical to endogenous progesterone).

Testosterone: Used off-label in the US for hypoactive sexual desire disorder (HSDD) in postmenopausal women; the Endocrine Society identifies testosterone therapy as having a supported evidence base for this indication (Endocrine Society Clinical Practice Guideline, 2014).

Delivery mechanisms determine absorption kinetics, first-pass hepatic metabolism, and systemic versus local hormone concentrations:

• Oral tablets — undergo hepatic first-pass metabolism, affecting coagulation factor synthesis and SHBG production
• Transdermal patches, gels, and sprays — bypass hepatic metabolism; associated with lower venous thromboembolism (VTE) risk in observational data
• Vaginal rings, creams, and suppositories — deliver estrogen locally with minimal systemic absorption; indicated for genitourinary syndrome of menopause (GSM)
• Subcutaneous implants and injections — less commonly used; produce sustained hormone delivery with less precise dose titration

Causal Relationships or Drivers

Hormonal decline in menopause drives a cascade of physiological changes that HRT targets at the mechanism level:

Vasomotor symptoms (hot flashes, night sweats): Caused by thermoregulatory instability linked to estrogen withdrawal effects on the hypothalamic thermostat. Estrogen therapy reduces hot flash frequency by approximately 75% compared with placebo across randomized controlled trials (Cochrane Review: Menopausal Hormone Therapy for Primary Prevention, 2017).

Bone loss: Estrogen suppresses osteoclast-mediated bone resorption. Postmenopausal women lose bone at 1–3% per year on average in the early postmenopausal years without intervention, elevating fracture risk (NIH Osteoporosis and Related Bone Diseases National Resource Center). HRT maintains bone mineral density and reduces vertebral and hip fracture incidence, as demonstrated in the WHI trial data.

Genitourinary syndrome of menopause (GSM): Low estrogen causes vulvovaginal atrophy, urinary urgency, and recurrent urinary tract infections. Local vaginal estrogen directly addresses the atrophic epithelium. For further detail on urinary health intersections, see urinary tract health in women.

Cardiovascular effects: Estrogen modulates lipid profiles, vascular tone, and inflammatory markers. The timing of initiation relative to menopause onset — the "timing hypothesis" or "window of opportunity" — appears to determine whether cardiovascular effects are protective or neutral/adverse, based on WHI subgroup analyses and the KEEPS (Kronos Early Estrogen Prevention Study) trial.

Classification Boundaries

HRT formulations are classified along four axes that determine clinical and regulatory categorization:

1. Hormonal composition
- Estrogen-only (ET): For women without a uterus
- Combined estrogen-progestogen (EPT): For women with an intact uterus
- Testosterone-containing: Adjunct for specific indications

2. Progestogen type
- Synthetic progestins (e.g., medroxyprogesterone acetate, MPA)
- Micronized bioidentical progesterone (e.g., Prometrium, FDA-approved)
- "Compounded bioidentical" hormones: Not FDA-approved as a category; the FDA has issued guidance distinguishing compounded preparations from approved bioidentical products

3. Route of administration
- Systemic (oral, transdermal, injectable, implant)
- Local/vaginal (ring, cream, tablet, suppository)

4. Regulatory approval status
- FDA-approved: Specific products with reviewed safety and efficacy data
- Compounded: Prepared by compounding pharmacies; not FDA-approved for safety or efficacy; subject to oversight under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and USP standards

The FDA's Center for Drug Evaluation and Research maintains a list of approved menopausal hormone products.

Tradeoffs and Tensions

The HRT evidence landscape is shaped by genuine clinical complexity, not simply knowledge gaps.

Breast cancer risk: The WHI EPT arm (estrogen plus MPA) found a relative risk increase for breast cancer of approximately 1.26 after 5.6 years of use (Rossouw et al., JAMA, 2002, Vol. 288, No. 3). The estrogen-only arm (women post-hysterectomy) showed a reduced breast cancer risk at 7.2 years. The type of progestogen appears to matter: observational data from France and the UK suggest micronized progesterone carries lower breast cancer risk than synthetic progestins, though randomized trial confirmation remains limited.

Cardiovascular risk versus benefit: Oral estrogen increases VTE risk approximately 2-fold compared with non-use; transdermal estrogen does not appear to carry the same VTE elevation in large observational studies (BMJ Million Women Study reference; ESTHER study, Canonico et al., 2007). Initiating therapy more than 10 years after menopause or after age 60 appears associated with higher coronary risk, while initiation within 10 years of menopause does not show the same hazard in multiple analyses.

Endometrial protection: Progestogen type, dose, and regimen (continuous vs. cyclical) affect endometrial safety. Cyclical regimens allow scheduled withdrawal bleeds; continuous combined regimens aim for amenorrhea. Levonorgestrel-releasing intrauterine systems (LNG-IUS) provide local endometrial protection without systemic progestogen exposure, a route recognized by the British Menopause Society as an evidence-supported option.

Symptom relief versus duration of therapy: Symptom recurrence after HRT discontinuation is common. Clinical societies including the North American Menopause Society (NAMS) do not endorse arbitrary time limits on duration when the clinical indication persists and risks are reviewed.

Common Misconceptions

Misconception 1: All HRT carries the same breast cancer risk.
Correction: Risk differs by formulation. Estrogen-only therapy in post-hysterectomy women showed no increased breast cancer incidence in the WHI trial at 7 years; the risk increase observed in the WHI was specific to combined estrogen-plus-MPA therapy.

Misconception 2: "Bioidentical" compounded hormones are safer than FDA-approved products.
Correction: The FDA has explicitly stated that compounded bioidentical hormone preparations have not been reviewed for safety or efficacy and cannot be labeled as safer alternatives. The term "bioidentical" refers to molecular structure, not regulatory approval status (FDA Statement on Compounded Menopausal Hormone Therapy).

Misconception 3: HRT causes heart attacks in all women.
Correction: The WHI finding of increased cardiovascular events applied to an older population (average age 63) initiating therapy many years after menopause. The timing hypothesis, supported by KEEPS and the Danish Osteoporosis Prevention Study, indicates a different risk profile for women who initiate HRT close to menopause onset.

Misconception 4: Local vaginal estrogen is equivalent to systemic HRT in risk.
Correction: Low-dose vaginal estrogen produces minimal systemic absorption and is not classified the same as systemic HRT for risk stratification. NAMS and the American College of Obstetricians and Gynecologists (ACOG) distinguish these categories in clinical guidance.

For a broader view of the evidence base shaping women's health decisions, the Women's Health Authority index provides orientation across health topics.

Checklist or Steps (Non-Advisory)

The following represents a structural framework for what a comprehensive HRT evaluation process includes — not a substitute for individualized clinical assessment.

Elements typically addressed in an HRT clinical evaluation:

• [ ] Symptom inventory: vasomotor, genitourinary, sleep disruption, mood changes, musculoskeletal
• [ ] Menstrual and reproductive history documentation
• [ ] Surgical history (hysterectomy, oophorectomy status — determines estrogen-only vs. combined therapy eligibility)
• [ ] Cardiovascular risk factor assessment: hypertension, dyslipidemia, smoking history, BMI, personal or family history of VTE
• [ ] Personal and family history of breast cancer, endometrial cancer, and hormone-sensitive malignancies
• [ ] Bone density status (DEXA scan results if available) — relevant to osteoporosis and bone health in women
• [ ] Current medications and potential interactions (especially anticoagulants, CYP3A4 inducers/inhibitors)
• [ ] Formulation preference discussion (oral, transdermal, vaginal, implant) based on VTE and hepatic considerations
• [ ] Baseline labs as indicated (lipids, thyroid function, hormone levels)
• [ ] Review of FDA-approved product labeling for selected formulation
• [ ] Established follow-up schedule for benefit-risk reassessment

Reference Table or Matrix

HRT Formulation Comparison Matrix

VTE = venous thromboembolism. Risk comparisons based on observational data, not head-to-head RCTs. Route-specific VTE data from ESTHER study (Canonico et al., 2007) and related European cohort analyses.

References

• NIH National Institute on Aging — Hormones and Menopause
• FDA — Menopause Medicines: Help for Your Symptoms
• FDA — Questions and Answers: Compounded Menopausal Hormone Therapy
• North American Menopause Society (NAMS)
• [American College of Obstetricians and Gynecologists (ACOG) — Practice Bulletin No. 141: Management of Menopausal

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)